Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.

Buturovic BA, Ristic LB, Narancic AM

Medical archives (Sarajevo, Bosnia and Herzegovina)15 Oct 2014Cited by 2 (Europe PMC)

PMID25568561PMCIDPMC4269541DOI10.5455/medarh.2014.68.313-316PepBankPUB-25568561

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In obese patients with poorly controlled glycaemia, switching to basal insulin analogue, metformin and liraglutide 0.6 mg lowered BMI to 28.2 kg/m2 after 12 weeks.
In plain wordsIn obese patients with poorly controlled blood sugar, a regimen of long-acting insulin, metformin and liraglutide was followed by lower BMI after 12 weeks.
Peptide
Liraglutide
Outcome
DecreaseBMI after 12 weeks
Study
n = 30
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
BMI
28.2 kg/m2
after 12 weeks
Source sentences
Summary
BMI value after the test was 28.2±1.39 kg/m2, p=0.025
3 context sentences(design, population, supporting numbers)
Summary · context
After 12 weeks of the new therapeutic regimen we recorded a significant reduction in the parameter levels that we monitored in the study.
Summary · context
The study included 30 patients who had been treated with long-acting insulin analogue and metformin in doses of 3 x 850 mg at least 6 months prior to study entry and in which a good glycaemic control had not been achieved, or with HbA1c > 7%.
Summary · context
At the beginning of the study the patients were switched to combined therapy with long-acting basal analog, metformin and liraglutide in a dosage of 0.6 mg of 1x1.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2556856101
02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In obese patients with poorly controlled glycaemia, a regimen of basal insulin analogue, metformin and liraglutide was followed by a reduction of body weight over 12 weeks.
In plain wordsIn obese patients with poorly controlled blood sugar, a regimen of long-acting insulin, metformin and liraglutide was followed by weight loss over 12 weeks.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n = 30
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
During research that we have conducted over 12 weeks, a reduction of body weight was achieved while improving the value of parameters significant for the study.
2 context sentences(design, population, supporting numbers)
Summary · context
The study included 30 patients who had been treated with long-acting insulin analogue and metformin in doses of 3 x 850 mg at least 6 months prior to study entry and in which a good glycaemic control had not been achieved, or with HbA1c > 7%.
Summary · context
At the beginning of the study the patients were switched to combined therapy with long-acting basal analog, metformin and liraglutide in a dosage of 0.6 mg of 1x1.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2556856102
03HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In obese patients with poorly controlled glycaemia, a regimen of basal insulin analogue, metformin and liraglutide lowered HbA1c to 7.24% after 12 weeks.
In plain wordsIn obese patients with poorly controlled blood sugar, a regimen of long-acting insulin, metformin and liraglutide was followed by lower HbA1c after 12 weeks.
Peptide
Liraglutide
Outcome
DecreaseHbA1c after 12 weeks
Study
n = 30
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c
7.24%
after 12 weeks
Source sentences
Summary
HbA1c 7.24±0.47%, p=0.030
3 context sentences(design, population, supporting numbers)
Summary · context
After 12 weeks of the new therapeutic regimen we recorded a significant reduction in the parameter levels that we monitored in the study.
Summary · context
The study included 30 patients who had been treated with long-acting insulin analogue and metformin in doses of 3 x 850 mg at least 6 months prior to study entry and in which a good glycaemic control had not been achieved, or with HbA1c > 7%.
Summary · context
At the beginning of the study the patients were switched to combined therapy with long-acting basal analog, metformin and liraglutide in a dosage of 0.6 mg of 1x1.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2556856103
04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In obese patients with poorly controlled glycaemia, a regimen of basal insulin analogue, metformin and liraglutide lowered fasting blood glucose to 7.04 mmol/l after 12 weeks.
In plain wordsIn obese patients with poorly controlled blood sugar, a regimen of long-acting insulin, metformin and liraglutide was followed by lower fasting glucose after 12 weeks.
Peptide
Liraglutide
Outcome
DecreaseFasting blood glucose after 12 weeks
Study
n = 30
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Measurements
Fasting blood glucose
7.04 mmol/l
after 12 weeks
Source sentences
Summary
fasting blood glucose level 7.04±0.32 mmol/l, p=0.023
3 context sentences(design, population, supporting numbers)
Summary · context
After 12 weeks of the new therapeutic regimen we recorded a significant reduction in the parameter levels that we monitored in the study.
Summary · context
The study included 30 patients who had been treated with long-acting insulin analogue and metformin in doses of 3 x 850 mg at least 6 months prior to study entry and in which a good glycaemic control had not been achieved, or with HbA1c > 7%.
Summary · context
At the beginning of the study the patients were switched to combined therapy with long-acting basal analog, metformin and liraglutide in a dosage of 0.6 mg of 1x1.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2556856104
05HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In obese patients with poorly controlled glycaemia, a regimen of basal insulin analogue, metformin and liraglutide lowered postprandial glucose to 7.6 mmol/l after 12 weeks.
In plain wordsIn obese patients with poorly controlled blood sugar, a regimen of long-acting insulin, metformin and liraglutide was followed by lower after-meal glucose after 12 weeks.
Peptide
Liraglutide
Outcome
DecreasePostprandial glucose after 12 weeks
Study
n = 30
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Measurements
Postprandial glucose
7.6 mmol/l
after 12 weeks
Source sentences
Summary
postprandial glucose level 7.6±0.46 mmol/l, p=0.012
3 context sentences(design, population, supporting numbers)
Summary · context
After 12 weeks of the new therapeutic regimen we recorded a significant reduction in the parameter levels that we monitored in the study.
Summary · context
The study included 30 patients who had been treated with long-acting insulin analogue and metformin in doses of 3 x 850 mg at least 6 months prior to study entry and in which a good glycaemic control had not been achieved, or with HbA1c > 7%.
Summary · context
At the beginning of the study the patients were switched to combined therapy with long-acting basal analog, metformin and liraglutide in a dosage of 0.6 mg of 1x1.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2556856105
06HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In obese patients with poorly controlled glycaemia, a regimen of basal insulin analogue, metformin and liraglutide lowered systolic blood pressure to 123 mmHg after 12 weeks.
In plain wordsIn obese patients with poorly controlled blood sugar, a regimen of insulin, metformin and liraglutide was followed by lower systolic blood pressure after 12 weeks.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure after 12 weeks
Study
n = 30
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Measurements
Systolic blood pressure
123 mmHg
after 12 weeks
Source sentences
Summary
systolic blood pressure level 123±5.75 mmHg, p=0.015
3 context sentences(design, population, supporting numbers)
Summary · context
After 12 weeks of the new therapeutic regimen we recorded a significant reduction in the parameter levels that we monitored in the study.
Summary · context
The study included 30 patients who had been treated with long-acting insulin analogue and metformin in doses of 3 x 850 mg at least 6 months prior to study entry and in which a good glycaemic control had not been achieved, or with HbA1c > 7%.
Summary · context
At the beginning of the study the patients were switched to combined therapy with long-acting basal analog, metformin and liraglutide in a dosage of 0.6 mg of 1x1.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2556856106
07HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In obese patients with poorly controlled glycaemia, a regimen of basal insulin analogue, metformin and liraglutide lowered diastolic blood pressure to 79.1 mmHg after 12 weeks.
In plain wordsIn obese patients with poorly controlled blood sugar, a regimen of insulin, metformin and liraglutide was followed by lower diastolic blood pressure after 12 weeks.
Peptide
Liraglutide
Outcome
DecreaseDiastolic blood pressure after 12 weeks
Study
n = 30
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Measurements
Diastolic blood pressure
79.1 mmHg
after 12 weeks
Source sentences
Summary
diastolic blood pressure level 79.1±2.91 mmHg, p=0.03.
3 context sentences(design, population, supporting numbers)
Summary · context
After 12 weeks of the new therapeutic regimen we recorded a significant reduction in the parameter levels that we monitored in the study.
Summary · context
The study included 30 patients who had been treated with long-acting insulin analogue and metformin in doses of 3 x 850 mg at least 6 months prior to study entry and in which a good glycaemic control had not been achieved, or with HbA1c > 7%.
Summary · context
At the beginning of the study the patients were switched to combined therapy with long-acting basal analog, metformin and liraglutide in a dosage of 0.6 mg of 1x1.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2556856107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.